Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) and Apellis Pharmaceuticals (NASDAQ:APLS) Head to Head Analysis

Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, profitability, valuation, dividends and earnings.

Institutional & Insider Ownership

96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 27.2% of Sienna Biopharmaceuticals shares are owned by company insiders. Comparatively, 6.8% of Apellis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Sienna Biopharmaceuticals and Apellis Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sienna Biopharmaceuticals	N/A	N/A	N/A
Apellis Pharmaceuticals	-34.97%	-103.11%	-28.96%

Earnings & Valuation

This table compares Sienna Biopharmaceuticals and Apellis Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sienna Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
Apellis Pharmaceuticals	$396.59 million	9.39	-$528.63 million	($2.03)	-14.74

Sienna Biopharmaceuticals has higher earnings, but lower revenue than Apellis Pharmaceuticals.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Sienna Biopharmaceuticals and Apellis Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sienna Biopharmaceuticals	0	0	0	0	0.00
Apellis Pharmaceuticals	0	8	10	1	2.63

Apellis Pharmaceuticals has a consensus target price of $46.65, suggesting a potential upside of 55.85%. Given Apellis Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than Sienna Biopharmaceuticals.

Summary

Apellis Pharmaceuticals beats Sienna Biopharmaceuticals on 6 of the 10 factors compared between the two stocks.

About Sienna Biopharmaceuticals

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California. On December 18, 2019, Sienna Biopharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 16, 2019.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam’s base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.